PMID- 31511432
OWN - NLM
STAT- MEDLINE
DCOM- 20200918
LR  - 20200918
IS  - 1573-4935 (Electronic)
IS  - 0144-8463 (Print)
IS  - 0144-8463 (Linking)
VI  - 39
IP  - 9
DP  - 2019 Sep 30
TI  - Wnt/beta-catenin signaling as a useful therapeutic target in hepatoblastoma.
LID - BSR20192466 [pii]
LID - 10.1042/BSR20192466 [doi]
AB  - Hepatoblastoma is a malignant tumor in the liver of children that generally 
      occurs at the age of 2-3 years. There have been ample evidence from the 
      preclinical as well as clinical studies suggesting the activation of 
      Wnt/beta-catenin signaling in hepatoblastoma, which is mainly attributed to the 
      somatic mutations in the exon 3 of beta-catenin gene. There is increased 
      translocation of beta-catenin protein from the cell surface to cytoplasm and nucleus 
      and intracellular accumulation is directly linked to the severity of the cancer. 
      Accordingly, the alterations in beta-catenin and its target genes may be used as 
      markers in the diagnosis and prognosis of pediatric live tumors. Furthermore, 
      scientists have reported the therapeutic usefulness of inhibition of 
      Wnt/beta-catenin signaling in hepatoblastoma and this inhibition of signaling has 
      been done using different methods including short interfering RNA (siRNA), miRNA 
      and pharmacological agents. Wnt/beta-catenin works in association with other 
      signaling pathways to induce the development of hepatoblastoma including 
      Yes-associated protein (YAP)1 (YAP-1), mammalian target of rapamycin (mTOR) 1 
      (mTOR-1), SLC38A1, glypican 3 (GPC3), nuclear factor kappa-light-chain-enhancer of 
      activated B cells (NF-kB), epidermal growth factor receptor, ERK1/2, tumor 
      necrosis factor-alpha (TNF-alpha), regenerating islet-derived 1 and 3 alpha (REG1A and 3A), 
      substance P (SP)/neurokinin-1 receptor and PARP-1. The present review describes 
      the key role of Wnt/beta-catenin signaling in the development of hepatoblastoma. 
      Moreover, the role of other signaling pathways in hepatoblastoma in association 
      with Wnt/beta-catenin has also been described.
CI  - (c) 2019 The Author(s).
FAU - Sha, Ying-Li
AU  - Sha YL
AD  - Department of Pediatric, The First Hospital of Jilin University-The Eastern 
      Division, Changchun, Jilin, China.
FAU - Liu, Shuang
AU  - Liu S
AD  - Department of Nursing Management, The First Hospital of Jilin University-The 
      Eastern Division, Changchun, Jilin, China.
FAU - Yan, Wen-Wen
AU  - Yan WW
AD  - Department of Pediatric, The First Hospital of Jilin University-The Eastern 
      Division, Changchun, Jilin, China.
FAU - Dong, Bo
AU  - Dong B
AUID- ORCID: 0000-0002-4531-8165
AD  - Department of Pediatric, The First Hospital of Jilin University-The Eastern 
      Division, Changchun, Jilin, China dong_bo@aliyun.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190924
PL  - England
TA  - Biosci Rep
JT  - Bioscience reports
JID - 8102797
RN  - 0 (CTNNB1 protein, human)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (beta Catenin)
SB  - IM
MH  - Cell Proliferation/genetics
MH  - Gene Expression Regulation, Neoplastic/genetics
MH  - Hepatoblastoma/*genetics/pathology
MH  - Humans
MH  - Liver Neoplasms/*genetics/pathology
MH  - Neoplasm Proteins/*genetics
MH  - Wnt Signaling Pathway/genetics
MH  - beta Catenin/*genetics
PMC - PMC6757184
OTO - NOTNLM
OT  - NF-kB
OT  - TNF-alpha
OT  - Wnt
OT  - hepatoblastoma
OT  - beta-catenin
COIS- The authors declare that there are no competing interests associated with the 
      manuscript.
EDAT- 2019/09/13 06:00
MHDA- 2020/09/20 06:00
PMCR- 2019/09/24
CRDT- 2019/09/13 06:00
PHST- 2019/07/16 00:00 [received]
PHST- 2019/08/24 00:00 [revised]
PHST- 2019/08/27 00:00 [accepted]
PHST- 2019/09/13 06:00 [pubmed]
PHST- 2020/09/20 06:00 [medline]
PHST- 2019/09/13 06:00 [entrez]
PHST- 2019/09/24 00:00 [pmc-release]
AID - BSR20192466 [pii]
AID - 10.1042/BSR20192466 [doi]
PST - epublish
SO  - Biosci Rep. 2019 Sep 24;39(9):BSR20192466. doi: 10.1042/BSR20192466. Print 2019 
      Sep 30.